SpyBiotech Appoints Keith Dewedoff as Chief Financial Officer

SpyBiotech, a biotechnology company at the forefront of developing novel vaccine platform technologies, has recently appointed Keith Dewedoff as Chief Financial Officer (CFO). With over 20 years of experience in the life science industry, Keith brings a wealth of knowledge and expertise to SpyBiotech.

Prior to joining SpyBiotech, Keith served as CFO and Advisor for Danforth Advisors, where he focused on providing financial strategy to life science organizations. He has also held CFO positions at various biotech venture-backed start-ups and commercial publicly traded companies, including Ceptur Therapeutics. Keith’s responsibilities have encompassed managing finance, accounting, corporate development, and other operational functions.

In a statement, Keith expressed his excitement about joining SpyBiotech during a pivotal time for the company, especially with the recent research collaboration with the University of Oxford and the Phase I trial of its HCMV vaccine. Mark Leuchtenberger, CEO of SpyBiotech, also praised Keith’s expertise in financial strategy and corporate development, highlighting his valuable contribution to the company’s leadership team.

SpyBiotech, which was spun out of the University of Oxford in 2017, focuses on developing vaccine platform technologies for infectious diseases, cancer, and chronic diseases. The company’s proprietary protein “superglue” technology binds antigens to vaccine delivery platforms, enhancing immunogenicity and efficacy. With a recent Series A equity financing of $32.5 million, SpyBiotech is poised for further advancements in vaccine development.

Keith Dewedoff’s appointment as CFO signifies a significant milestone for SpyBiotech as the company continues to expand its scientific pipeline and make strides in vaccine development. With his extensive experience and strategic vision, Keith is expected to play a key role in driving SpyBiotech’s growth and success in the biotechnology industry.